Literature DB >> 11140609

Carbonic anhydrase inhibitors: synthesis of Schiff bases of hydroxybenzaldehydes with aromatic sulfonamides and their reactions with arylsulfonyl isocyanates.

A Scozzafava1, M D Banciu, A Popescu, C T Supuran.   

Abstract

Reaction of o- or p-hydroxybenzaldehydes with sulfanilamide, homosulfanilamide and p-(2-aminoethyl)- benzene-sulfonamide afforded several new Schiff bases which were subsequently derivatized at the phenolic hydroxy moiety by reaction with arylsulfonylisocyanates. The new arylsulfonylcarbamates obtained in this way possessed interesting inhibitory properties against three carbonic anhydrase (CA) isozymes, hCA I, hCA II and bCA IV (h = human, b = bovine isozyme). All these new derivatives, the simple Schiff bases and the arylsulfonylcarbamates obtained as outlined above, were more inhibitory against all isozymes as compared to the corresponding parent sulfonamide from which they were obtained. Generally, the p-hydroxybenzaldehyde derivatives were more active than the corresponding ortho isomers. An interesting behavior was evidenced for some of the ortho-substituted arylsulfonylcarbamato-sulfonamides, which showed higher affinities for the isozyme hCA I, as compared to hCA II and bCA IV (generally hCA I is 10-1000 less sensitive to "normal" sulfonamide inhibitors, such as acetazolamide, methazolamide or dorzolamide, as compared to hCA II). This make the new derivatives attractive leads for designing isozyme I-specific inhibitors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11140609     DOI: 10.3109/14756360009040708

Source DB:  PubMed          Journal:  J Enzyme Inhib        ISSN: 1026-5457


  1 in total

1.  Design, synthesis, molecular modeling, and biological evaluation of sulfanilamide-imines derivatives as potential anticancer agents.

Authors:  Sofian S Mohamed; Abdalkarem R Tamer; Salah M Bensaber; Mousa I Jaeda; Nouri B Ermeli; Aemen Ali Allafi; Ibrahim A Mrema; Mabrouk Erhuma; Anton Hermann; Abdul M Gbaj
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-05-26       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.